The influence of acute coronary syndrome on levels of clopidogrel active metabolite and platelet inhibition in patients with and without CYP2C19*2(681 G>A), *3(636 G>A) and ABCB1(C3435C> T) gene polymorphisms.

MLA

Wójcik, Tomasz, et al. “The Influence of Acute Coronary Syndrome on Levels of Clopidogrel Active Metabolite and Platelet Inhibition in Patients with and without CYP2C19*2(681 G>A), *3(636 G>A) and ABCB1(C3435C> T) Gene Polymorphisms.” Advances in Interventional Cardiology / Postępy w Kardiologii Interwencyjnej, vol. 17, no. 2, Apr. 2021, pp. 179–86. EBSCOhost, https://doi.org/10.5114/aic.2021.106894.

APA

Wójcik, T., Karolko, B., Wiśniewski, J., Mysiak, A., Ściborski, K., Onisk, G., Lebioda, A., Jonkisz, A., & Protasiewicz, M. (2021). The influence of acute coronary syndrome on levels of clopidogrel active metabolite and platelet inhibition in patients with and without CYP2C19*2(681 G>A), *3(636 G>A) and ABCB1(C3435C> T) gene polymorphisms. Advances in Interventional Cardiology / Postępy w Kardiologii Interwencyjnej, 17(2), 179–186. https://doi.org/10.5114/aic.2021.106894

Chicago

Wójcik, Tomasz, Bożena Karolko, Jerzy Wiśniewski, Andrzej Mysiak, Krzysztof Ściborski, Grzegorz Onisk, Arleta Lebioda, Anna Jonkisz, and Marcin Protasiewicz. 2021. “The Influence of Acute Coronary Syndrome on Levels of Clopidogrel Active Metabolite and Platelet Inhibition in Patients with and without CYP2C19*2(681 G>A), *3(636 G>A) and ABCB1(C3435C> T) Gene Polymorphisms.” Advances in Interventional Cardiology / Postępy w Kardiologii Interwencyjnej 17 (2): 179–86. doi:10.5114/aic.2021.106894.